- Report
- October 2022
- 70 Pages
Africa
From €4315EUR$4,750USD£3,725GBP
- Report
- June 2025
- 400 Pages
Global
From €4496EUR$4,949USD£3,881GBP
- Report
- May 2024
- 93 Pages
Global
From €13622EUR$14,995USD£11,760GBP
- Report
- February 2024
- 245 Pages
Global
€4538EUR$4,995USD£3,917GBP
- Report
- May 2026
- 150 Pages
Australia
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
Brazil
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
Canada
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
Germany
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
India
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
Indonesia
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
Italy
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
Japan
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
Malaysia
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
Mexico
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
Netherlands
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
China
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
Saudi Arabia
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
South Africa
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
South Korea
From €4406EUR$4,850USD£3,804GBP
- Report
- May 2026
- 150 Pages
Spain
From €4406EUR$4,850USD£3,804GBP

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an anti-obesity drug. It is a long-acting analogue of human GLP-1, a hormone that is released in response to food intake. Liraglutide works by stimulating the release of insulin and suppressing appetite. It is typically prescribed as an adjunct to diet and exercise for the treatment of obesity. It is also used to treat type 2 diabetes.
Liraglutide is available in both injectable and oral formulations. The injectable form is administered subcutaneously once daily, while the oral form is taken once daily with food. Common side effects of liraglutide include nausea, vomiting, diarrhea, and abdominal pain.
Several companies are involved in the liraglutide market, including Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less Read more